Albireo to Report Third Quarter 2021 Financial Results on November 4
Albireo Pharma (Nasdaq: ALBO) will host a conference call on November 4, 2021 at 10:00 a.m. ET to discuss its Q3 2021 financial results. The call will be accessible via phone or through a live audio webcast on the company's website. Albireo is focused on developing novel bile acid modulators to treat rare liver diseases. Its lead product, Bylvay (odevixibat), has received FDA approval for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and is also being evaluated for other rare liver diseases.
- Lead product Bylvay approved by the U.S. FDA for PFIC treatment.
- Ongoing Phase 3 trials for Alagille syndrome and biliary atresia.
- Initiated a Phase 1 clinical trial for A3907 targeting adult cholestatic liver disease.
- None.
— Conference call and webcast to be held at 10:00 a.m. ET —
BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on November 4, 2021, to provide a business update and review the company’s financial results for the third quarter ended September 30, 2021.
To access the live conference call by phone, please dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13723976. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, https://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, BylvayTM (odevixibat), was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC and has been submitted for pricing and reimbursement approval. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lauren Sneider, 857-300-1737, lauren.sneider@albireopharma.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
What time will Albireo Pharma's conference call take place?
How can I access the Albireo Pharma conference call?
What is Albireo Pharma's lead product?
What trials is Albireo Pharma currently conducting?
